YOLFTbeta
Wave Life Sciences Ltd

Wave Life Sciences Ltd

WVE · NASDAQ · Healthcare / Biotechnology

3.13USD-0.02 (-0.79%)

Price History

Full chart

Market Stats

Previous Close3.16
Open3.12
Day Range3.00 – 3.20
52-Week Range3.56 – 21.73
Volume2.65M
Market Cap717.26M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.07
Dividend Yield0.00%
Beta-1.30
50-Day Avg5.08
200-Day Avg8.88

About

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Paul B. Bolno M.B.A., M.D.
  • Employees317
  • Headquarters733 Concord Avenue, Cambridge, MA, United States, 02138, USA
  • Websitehttps://wavelifesciences.com

Leadership

  • Dr. Paul B. Bolno M.B.A., M.D.President, CEO & Director · b. 1974
  • Dr. Gregory L. Verdine Ph.D.Founder & Director · b. 1959
  • Mr. Kyle B. Moran CFACFO & Principal Accounting Officer · b. 1971
  • Dr. Chandra Vargeese Ph.D.Chief Technology Officer · b. 1961
  • Dr. Christopher Francis Ph.D.Senior VP of Corporate Development & Head of Emerging Areas · b. 1978
  • Dr. Erik Ingelsson M.D., Ph.D.Chief Scientific Officer
  • Ms. Linda Rockett J.D.Senior VP & General Counsel

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0152.00K1.49M3.70M14.41M15.98M20.08M40.96M3.65M113.31M108.30M42.73M
Growth (%)---+876.97%+149.43%+289.15%+10.89%+25.61%+104.03%-91.09%+3005.10%-4.42%-60.55%
Cost of Revenue4.61M2.40M9.06M393.00K79.31M134.43M175.43M130.94M121.88M10.11M9.21M8.66M8.85M
Gross Profit-4.61M-2.40M-8.90M1.09M-75.61M-120.01M-159.45M-110.87M40.96M3.65M113.31M108.30M33.88M
Gross Margin---5858.55%73.54%-2041.17%-832.62%-997.61%-552.21%100.00%100.00%100.00%100.00%79.28%
Operating Expense-1.03M3.00M10.39M56.42M26.98M39.51M48.87M42.51M167.98M166.37M181.30M218.71M249.26M
Operating Income-3.57M-5.39M-19.30M-55.33M-102.58M-159.52M-208.32M-153.38M-127.02M-162.72M-68.00M-110.40M-215.38M
Operating Margin---12696.05%-3725.72%-2769.44%-1106.72%-1303.37%-763.94%-310.07%-4459.30%-60.01%-101.94%-504.09%
EBITDA-3.26M-5.11M-18.56M-54.94M-100.24M-153.94M-200.73M-145.26M-112.61M-152.61M-48.98M-88.34M-195.53M
EBITDA Margin---12211.84%-3699.39%-2706.16%-1068.00%-1255.89%-723.53%-274.91%-4182.13%-43.23%-81.57%-457.62%
Net Income-3.32M-5.23M-19.20M-55.40M-102.03M-146.65M-193.64M-149.91M-122.25M-161.82M-57.51M-97.01M-204.38M
Net Income Margin---12631.58%-3730.71%-2754.72%-1017.43%-1211.52%-746.68%-298.42%-4434.72%-50.76%-89.57%-478.33%
R&D1.92M2.40M9.06M40.82M79.31M134.43M175.43M130.94M121.88M115.86M130.01M159.68M182.78M
R&D as % of Total Revenue--5958.55%2748.69%2141.17%932.62%1097.61%652.21%297.52%3175.01%114.74%147.44%427.78%
Interest Expense012.00K86.00K337.00K6.00K22.00K016.00K14.43M1.58M---
Interest Expense % of Total Revenue--56.58%22.69%0.16%0.15%0.00%0.08%35.23%43.24%---

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.32M2.94M165.42M164.81M181.84M295.94M284.25M279.24M207.01M146.39M274.95M352.21M638.50M
Total Liabilities10.09M911.00K11.93M29.95M42.03M222.59M212.64M188.59M174.51M191.48M235.32M142.69M112.27M
Total Equity-7.76M2.03M153.49M134.86M139.81M73.35M71.61M90.65M32.50M-45.09M39.63M209.51M526.23M
Cash439.00K1.05M161.22M150.29M142.50M174.82M147.16M184.50M150.56M88.50M200.35M302.08M602.07M
Total Debt9.60M-140.00K78.00K3.45M10.40M32.55M29.30M29.92M37.61M32.12M25.40M17.77M
Net Debt9.16M-1.05M-161.08M-150.22M-139.05M-164.42M-114.61M-155.19M-120.65M-50.88M-168.23M-276.67M-584.30M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.55M-4.43M-12.53M-31.87M-83.67M-22.86M-188.23M-115.98M-88.99M-127.78M-19.43M-151.03M-187.49M
Investing Cash Flow-47.00K-257.00K-2.91M-8.16M-18.90M-9.94M-3.92M-1.34M-560.00K-1.25M-1.11M-938.00K-718.00K
Financing Cash Flow3.67M5.62M175.59M29.12M94.37M65.09M164.40M154.54M55.83M67.19M132.53M253.89M488.24M
Capital Expenditure47.00K590.00K1.86M5.57M18.89M9.94M3.92M1.34M560.00K1.36M1.11M938.00K718.00K
Free Cash Flow-3.60M-5.02M-14.38M-37.44M-102.56M-32.80M-192.15M-117.32M-89.55M-129.14M-20.55M-151.96M-187.49M
Dividends Paid--113.08M30.00M0--------
FCF to OCF101.32%113.33%114.82%117.47%122.57%143.47%102.08%101.15%100.63%101.07%105.74%100.62%100.00%
Dividend Paid to FCF---786.12%-80.13%0.00%--------

Earnings

Report DateDec 17, 2015Mar 30, 2016May 16, 2016Aug 15, 2016Nov 9, 2016Mar 16, 2017May 10, 2017Aug 9, 2017Nov 9, 2017Mar 12, 2018May 9, 2018Aug 9, 2018Nov 9, 2018Mar 1, 2019May 10, 2019Jul 29, 2019Nov 5, 2019Mar 2, 2020May 11, 2020Aug 10, 2020Nov 9, 2020Mar 4, 2021May 13, 2021Aug 5, 2021Nov 10, 2021Mar 3, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 22, 2023May 3, 2023Aug 3, 2023Nov 9, 2023Mar 6, 2024May 10, 2024Aug 8, 2024Nov 12, 2024Mar 4, 2025May 8, 2025Jul 30, 2025Nov 10, 2025Feb 26, 2026Apr 28, 2026Jul 30, 2026Nov 9, 2026
EPS Estimate-0.27-0.28-0.39-0.37-0.53-0.75-0.76-0.81-0.98-1.00-0.91-1.10-1.24-1.15-1.20-1.00-1.37-1.43-1.32-1.07-0.73-0.61-0.59-0.62-0.61-0.51-0.55-0.53-0.50-0.41-0.04-0.33-0.22-0.23-0.20-0.22-0.30-0.17-0.26-0.28-0.30-0.28-0.31-0.31-0.33
EPS Actual-0.54-0.47-0.36-0.51-0.75-0.79-0.89-0.92-0.94-1.10-1.26-1.23-1.28-1.28-1.36-1.22-1.48-1.65-1.38-1.15-0.86-0.59-0.86-0.78-0.12-0.61-0.62-0.62-0.42-0.47-0.27-0.200.07-0.15-0.24-0.25-0.470.17-0.29-0.31-0.32-0.30-0.13-0.34-
Surprise-100.00%-67.86%7.69%-37.84%-41.51%-5.33%-17.11%-13.58%4.08%-10.00%-38.46%-11.82%-3.23%-11.30%-13.33%-22.00%-8.03%-15.38%-4.55%-7.48%-17.81%3.28%-45.76%-25.81%80.33%-19.61%-12.73%-16.98%16.00%-14.63%-575.00%39.39%131.82%34.78%-20.00%-13.64%-56.67%200.00%-11.54%-10.71%-6.67%-7.14%58.06%-9.68%-
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap717.26M
Enterprise Value331.33M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales10.97
Price / Book1.72
EPS-1.07
Book Value2.35
Revenue (TTM)65.37M
Gross Profit (TTM)-132.05M
EBITDA-214.52M
Profit Margin0.00%
Operating Margin-3248.33%
Return on Equity-67.42%
Return on Assets-33.60%
Shares Outstanding197.05M
Shares Float94.57M
Beta-1.30
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 13 analystsTarget 18.53
  • Strong Buy
    9
  • Buy
    3
  • Hold
    1

Ownership Breakdown

Institutions
85.26%
Insiders
15.50%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    26.98M13.69%
  • GSK PLC
    18.25M9.26%
  • BlackRock Inc
    14.12M7.16%
  • Maverick Capital Ltd
    10.16M5.16%
  • T. Rowe Price Associates, Inc.
    8.70M4.42%
  • Driehaus Capital Management LLC
    5.43M2.76%
  • PRIMECAP Management Company
    5.35M2.72%
  • FMR Inc
    5.19M2.64%
  • 683 Capital Management LLC
    4.90M2.49%
  • M28 Capital Management LP
    4.59M2.33%
  • Two Sigma Investments LLC
    3.71M1.88%
  • State Street Corp
    3.67M1.86%
  • Geode Capital Management, LLC
    3.58M1.82%
  • Algert Global LLC
    2.82M1.43%
  • Siren, L.L.C.
    2.45M1.24%
  • Pfizer Inc
    1.88M0.95%
  • Millennium Management LLC
    1.81M0.92%
  • Marshall Wace Asset Management Ltd
    1.79M0.91%

Top Fund Holders

  • PRIMECAP Odyssey Aggressive Growth
    4.11M2.09%
  • iShares Russell 2000 ETF
    3.54M1.80%